Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …

Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

In recent years, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs), gefitinib and erlotinib, which have promising activity and a favourable toxicity profile …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective
treatment for advanced non-small cell lung cancer. The objective of the present study was to …

Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as …

Introduction: The development of EGFR TKI and the subsequent identification of activating
EGFR mutations have dramatically changed how NSCLC is treated. With its recent approval …

Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been
approved in Japan for the treatment of patients with advanced non-small-cell lung cancer …

Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …

7504 Background: Somatic EGFR mutations correlate with increased response and survival
in NSCLC patients (pts) treated with gefitinib. We conducted the 1st prospective US trial of …

PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …